Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) Shares Outstanding (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Shares Outstanding data on record, last reported at $87.4 million in Q4 2025.

  • For Q4 2025, Shares Outstanding rose 2.0% year-over-year to $87.4 million; the TTM value through Dec 2025 reached $87.4 million, up 2.0%, while the annual FY2025 figure was $87.4 million, 2.0% up from the prior year.
  • Shares Outstanding reached $87.4 million in Q4 2025 per SNDX's latest filing, up from $86.9 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $87.4 million in Q4 2025 and bottomed at $48.2 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $71.0 million, with a median of $69.5 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: skyrocketed 59.55% in 2021, then grew 1.02% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $55.0 million in 2021, then increased by 23.88% to $68.1 million in 2022, then increased by 24.54% to $84.8 million in 2023, then rose by 1.02% to $85.7 million in 2024, then rose by 2.0% to $87.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $87.4 million in Q4 2025, $86.9 million in Q3 2025, and $86.1 million in Q2 2025.